Roche ’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
      ·Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone) plus placebo met its co-primary endpoint of radiographic progression free survival (rPFS) in patients with PTEN loss tumoursBasel, 19 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCR...
Source: Roche Media News - June 19, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: hPCL3S promotes proliferation and migration of androgen-independent prostate cancer cells
(Impact Journals LLC) The cover for issue 12 of Oncotarget features Figure 11, 'Global analyses of the RNA-Seq data of LNCaP empty vector and LNCaP cells overexpressing hPCL3S (Clone 12)' by Abdelfettah, et al. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 25, 2020 Category: Cancer & Oncology Source Type: news